Chan-Kou Hwang

This inventor holds 13 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Scripps Research Institute, Optimer Pharmaceuticals, Inc., Merck Sharp + Dohme Corp.. Active years: 1993-2015.

USPTO Granted Patents = 13 (Patent Applications = 4)

% Patents Active = 69.2

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 6.1

ph-index = 6

Forward Citations = 251(Granted Patents)

Company Filing History:

6 out of 1,205

Scripps Research Institute

patents

5 out of 16

Optimer Pharmaceuticals, Inc.

patents

1 out of 2,405

Merck Sharp + Dohme Corp.

patents

4. 1 out of 834,411

Other

patents

Years Active: 1993-2015

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9200026 - Antibacterial agents (2015-12-01),

2. 8586551 - 18-membered macrocycles and analogs thereof (2013-11-19),

3. 8343936 - Antibacterial agents (2013-01-01),

4. 8012943 - Antibacterial agents (2011-09-06),

5. 7906489 - 18-membered macrocycles and analogs thereof (2011-03-15),

6. 7601695 - Antibacterial agents (2009-10-13),

7. 5527805 - Dynemicin analogs: syntheses, methods of preparation and use (1996-06-18),

8. 5288761 - Open chain enediyne dihydroperoxides having DNA cleaving properties (1994-02-22),

9. 5281710 - Dynemicin analogs: synthesis, methods of preparation and use (1994-01-25),

10. 5276159 - Dynemicin analogs: syntheses, methods of preparation and use (1994-01-04),

11. 5274137 - Intermediates for preparation of taxols (1993-12-28),

12. 5264586 - Analogs of calicheamicin gamma1I, method of making and using the same (1993-11-23),

13. 5183942 - Ten-membered ring enediynediols and enediynediones having DNA cleaving (1993-02-02),

Title: The Innovative Contributions of Chan-Kou Hwang

Introduction

Chan-Kou Hwang is a prominent inventor based in San Diego, CA (US). He has made significant contributions to the field of antimicrobial agents, holding a total of 13 patents. His work focuses on developing novel macrolides and other compounds that have the potential to treat bacterial infections effectively.

Latest Patents

Hwang's latest patents include groundbreaking research on antibacterial agents. These patents describe novel macrolides, their preparation, and their use in preventing, treating, or ameliorating various conditions. Another significant patent involves 18-membered macrocycles and their analogs, specifically the antimicrobial agents known as Tiacumicins. One of these, OPT-80, is composed almost entirely of the R-Tiacumicin B and is recognized for its potency in treating bacterial infections.

Career Highlights

Throughout his career, Chan-Kou Hwang has worked with esteemed organizations such as The Scripps Research Institute and Optimer Pharmaceuticals, Inc. His research has contributed to advancements in the pharmaceutical industry, particularly in the development of effective treatments for bacterial infections.

Collaborations

Hwang has collaborated with notable scientists, including Kyriacos Costa Nicolaou and Youe-Kong Shue. These partnerships have further enhanced his research and innovation in the field of antimicrobial agents.

Conclusion

Chan-Kou Hwang's contributions to the field of antimicrobial research are noteworthy. His innovative patents and collaborations have the potential to significantly impact the treatment of bacterial infections.